Riemser strengthens international profile with new products in Canada and the UK

  • Riemser expands its product range for special pharmaceuticals in therapeutic niche areas.
  • Approval of Triamcinolone Hexacetonide in Canada closes a gap in regional supply for patients with juvenile arthritis.
  • Acquisition of distribution rights for Jylamvo in the UK facilitates the treatment of arthritis and psoriasis.

Berlin, January 22, 2018 – With the approval of Triamcinolone Hexacetonide in Canada and the acquisition of distribution rights for Jylamvo in the UK, Riemser Pharma GmbH (Riemser), a specialty pharmaceuticals company operating throughout Europe, is pressing ahead with its internationalization efforts. Approval of the active substance Triamcinolone Hexacetonide in Canada was completed in the shortest possible time of within just one year. As a result, it is closing a supply gap for patients in Canada who suffer from juvenile arthritis. Riemser already markets the active ingredient in 17 countries in Europe, Asia and South America under various trade names. In Germany, the drug is available under the name Lederlon. In the UK, the company has also acquired the distribution rights for Jylamvo for the English and Irish markets. Jylamvo facilitates the treatment of rheumatoid arthritis in children as well as in adults because it is taken in liquid form. It therefore accommodates many patients who do not tolerate the usual dosage form of the active ingredient methotrexate as either pills or injections. In addition, it is significantly cheaper than injections. With both milestones, Riemser sharpens its image as a focused supplier for specialty pharmaceuticals in therapeutic niches in the field of human medicine.

International distribution network as key to closing a supply gap with Triamcinolone Hexacetonide for adolescent patients in Canada

The introduction of Triamcinolone Hexacetonide in Canada was achieved, among other things, due to Riemser’s well-established international network. In Canada, around 24,000 patients under the age of 18 suffer from forms of arthritis – a painful, chronic, inflammatory disease of the joints that can lead to restricted mobility, irreversible joint damage and growth disorders. With the active ingredient Triamcinolone Hexacetonide, the symptoms can be eased considerably, even a temporary remission can be achieved. After the sole Canadian provider at the time had stopped distributing this active ingredient in 2014, patients’ and physicians’ associations turned to pharma company Medexus who approached Riemser and subsequently became one of the Canadian partner companies in Riemser’s global distribution network. Riemser has distributed Triamcinolone Hexacetonide under the German trade name Lederlon since 2001. On this basis, distribution of the imported drug initially started within the framework of the Canadian “Special Access Program” (SAP). At the end of 2016, Riemser and Medexus established a formal partnership and filed for approval of Triamcinolone Hexacetonide in Canada. Thanks to Riemser’s and Medexus’s expertise in such procedures, this approval was completed within the shortest possible time of just one year. As a result, Riemser can close the supply gap that had arisen in Canada among juvenile patients starting in spring 2018. The approval of Triamcinolone Hexacetonide in Canada is also an important step for Riemser to open up further markets for this drug.

Oral solution Jylamvo is an easy to administer and cost-effective alternative to pills and injections in pediatric patients

Jylamvo is a solution to administer the active ingredient methotrexate, which is used in children to treat various forms of arthritis and psoriasis as well as in pediatric oncology in patients with acute lymphoblastic leukemia (ALL). Administration in liquid form especially facilitates the treatment of children who do not tolerate the previously customary administration in the form of pills and shots – as well as for older people who suffer from swallowing disorders, for example. Furthermore, Jylamvo has a significant cost advantage over shots: the weekly costs for the treatment with Jylamvo amount to around GBP 8, whereas injections can cost several hundred British pounds. To date, two million packages of methotrexate pills and also a substantial number of injections are sold every year on the UK market. Due to the advantages associated with the ease of administration compared to shots, Riemser expects to gain significant market shares in the UK. Because the easier dosage form of the drug improves intake compliance, the oral solution benefits from a higher reimbursement price.

Specialization and flexibility enable the supply of niche therapeutic markets

Because of its specialized orientation and its company structure, Riemser is also able to profitably tap niche markets with relatively small numbers of patients. The company has a clear focus on defined therapeutic areas in oncology, infectiology and neurology with further focal areas in the cardiovascular field, in dermatology, rheumatology and in tuberculosis treatment. Except in the area of tuberculosis treatment, Riemser does not maintain own production facilities. This gives Riemser the flexibility to distribute batch sizes that are unattractive or economically unfeasible for broader based or larger pharmaceutical companies.

Konstantin von Alvensleben, CEO of Riemser, said: “Our task as a pharmaceutical company is to alleviate suffering and improve the quality of life. In recent years, we have invested a great deal of effort and funding in the evolution of Riemser into a focused and flexible provider of specialty pharmaceuticals in therapeutic niches as well as in our international distribution network. The approval of Triamcinolone Hexacetonide in Canada and the acquisition of distribution rights for Jylamvo in the UK fit perfectly into our strategy because, on the one hand, they expand our product range in two of our core indication areas – rheumatology and oncology – and, on the other hand, constitute important steps in the further expansion of Riemser’s international operations. Our well-established and strong international network has significantly contributed to the achievement of these achievements. Personally, I am especially pleased that both drugs particularly benefit children and adolescents.”


About Riemser Pharma GmbH

Riemser Pharma GmbH was established in 1992 and emerged from the Friedrich Löffler Institute on Riems Island (Greifswald). Riemser has been in business for more than 25 years, during which it has evolved from a manufacturer of veterinary medicines to a successful provider of specialty pharmaceuticals for therapeutic niches in the field of human medicine.

Riemser sells, licenses, markets and distributes pharmaceutical products. Over 400 approvals worldwide, of which 28 took place in the last three years, are a testament to the special expertise of Riemser for the approval and opening of new markets for pharmaceutical products.

The product range especially covers prescription drugs to treat serious diseases in the therapeutic areas of oncology, infectiology, neurology, in the cardiovascular field, in dermatology, rheumatology, tuberculosis treatment, for the treatment of obesity and primary hyperhidrosis. Medicinal products and food supplements complement the portfolio.

Besides its international group headquarters in Berlin, the company has three locations in Germany. In 2014 and 2015 Riemser acquired the subsidiaries Keocyt based in France and Intrapharm based in England. In addition, it has established an international distribution network. Riemser is a portfolio company of Ardian, one of the world’s leading private investment companies.

Press Contact
Charles Barker Corporate Communications GmbH

Jan P. Sefrin
jan.sefrin[at]charlesbarker[dot]de
Tel: +49 69 79409026

Tobias Eberle
tobias.eberle[at]charlesbarker[dot]de

Tel: +49 69 79409024